| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $24,411,331 ) |
| | 2025 | 2025 | TIGATX INC | 75 KNEELAND ST FL 14 | BOSTON | MA | 02111-1901 | SUFFOLK | USA | AY2AX000074 | Engineered Monomeric IgA Neutrophil-Engagers for Cancer | 002 | 1 | NIH | 4/21/2025 | $0 |
| | 2025 | 2025 | TIGATX INC | 75 KNEELAND ST FL 14 | BOSTON | MA | 02111-1901 | SUFFOLK | USA | AY2AX000074 | Engineered Monomeric IgA Neutrophil-Engagers for Cancer | 001 | 1 | NIH | 3/21/2025 | $0 |
| | 2025 | 2025 | TIGATX INC | 75 KNEELAND ST FL 14 | BOSTON | MA | 02111-1901 | SUFFOLK | USA | AY2AX000074 | Engineered Monomeric IgA Neutrophil-Engagers for Cancer | 000 | 1 | NIH | 12/20/2024 | $24,411,331 |
|
| Issue Date FY: 2024 ( Subtotal = $1,418,424 ) |
| | 2024 | 2024 | TIGATX INC | 75 KNEELAND ST FL 14 | BOSTON | MA | 02111-1901 | SUFFOLK | USA | R44CA291266 | Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers | 000 | 1 | NIH | 9/6/2024 | $1,418,424 |
|
|
